MedtronicWith 3 quarters of operations under its belt since the $50 billion acquisition of Covidien, Medtronic (NYSE:MDT) is evaluating whether to sell off some of the Covidien assets, CEO Omar Ishrak told analysts yesterday during a conference call.
Ishrak said Covidien, which Medtronic calls its minimally invasive therapies group, has “a very clear and compelling vision for the future, which is outcomes-based and very aligned with the Medtronic mission.”
The company will take the next 6 months or so to decide if there are any ex-Covidien assets it wants to divest, he said.
Ishrak said Covidien, which Medtronic calls its minimally invasive therapies group, has “a very clear and compelling vision for the future, which is outcomes-based and very aligned with the Medtronic mission.”
The company will take the next 6 months or so to decide if there are any ex-Covidien assets it wants to divest, he said.
